|
The Promega @cademy provides a tailored
programme of non-commercial live webinars,
covering a wide range of scientific topics, from
very basic concepts to highly technical research
presentations.
The title of this webinar is: "Multiplexed In
Vitro Viability and Cytotoxicity Methods for
Strengthening Predictive Confidence and
Improving Mechanistic Content".
This is a
Specialist webinar,
these webinars addresses more specialized
topics and are useful for PhD students and senior
scientists.
Information
A central tenet of pharmacology
is that all compounds have the capacity to induce toxicity due to dosage.
These specific toxicity thresholds are inherently linked to cellular
exposure period and cell-type susceptibility. Therefore, the practical
implementation of any in vitro testing methodology is greatly dependent upon
whether the study is designed to identify targeted cytotoxicity (oncology)
or potential off-target toxicity (safety). Either way, the traditional
experimental paradigm has been to triage data from large primary screening
sets, and then examine the –œactives– with a battery of secondary assays in
parallel. This talk will describe numerous same-well multiplex assay
combinations which may obviate parallel assays because they provide
immediate orthogonal or complementary measures useful for confirming
cytotoxicity or flagging non-conforming points for additional study. For
instance, viability and cytotoxicity assays can be added in meaningful
combinations with genetic reporter or cytochrome p450 assays, early measures
of cellular stress and apoptosis, or assays for specific obligate functional
activities. This proposed multiplex paradigm is designed to streamline data
acquisition efficiencies by reducing experimental effort, variability and
adding mechanistic content.
This webinar was presented by Andrew Niles,
Ph.D., R&D Scientist, Promega Corporation
This webinar was
presented in the past so registration is not possible
|